Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 28;117(30):17720-17726.
doi: 10.1073/pnas.2008410117. Epub 2020 Jul 9.

BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)

Luis E Escobar  1 , Alvaro Molina-Cruz  2 , Carolina Barillas-Mury  3
Affiliations

BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)

Luis E Escobar et al. Proc Natl Acad Sci U S A. .

Erratum in

Abstract

A series of epidemiological explorations has suggested a negative association between national bacillus Calmette-Guérin (BCG) vaccination policy and the prevalence and mortality of coronavirus disease 2019 (COVID-19). However, these comparisons are difficult to validate due to broad differences between countries such as socioeconomic status, demographic structure, rural vs. urban settings, time of arrival of the pandemic, number of diagnostic tests and criteria for testing, and national control strategies to limit the spread of COVID-19. We review evidence for a potential biological basis of BCG cross-protection from severe COVID-19, and refine the epidemiological analysis to mitigate effects of potentially confounding factors (e.g., stage of the COVID-19 epidemic, development, rurality, population density, and age structure). A strong correlation between the BCG index, an estimation of the degree of universal BCG vaccination deployment in a country, and COVID-19 mortality in different socially similar European countries was observed (r2 = 0.88; P = 8 × 10-7), indicating that every 10% increase in the BCG index was associated with a 10.4% reduction in COVID-19 mortality. Results fail to confirm the null hypothesis of no association between BCG vaccination and COVID-19 mortality, and suggest that BCG could have a protective effect. Nevertheless, the analyses are restricted to coarse-scale signals and should be considered with caution. BCG vaccination clinical trials are required to corroborate the patterns detected here, and to establish causality between BCG vaccination and protection from severe COVID-19. Public health implications of a plausible BCG cross-protection from severe COVID-19 are discussed.

Keywords: BCG vaccination policy; COVID-19 coronavirus; cross-protection; mortality; pandemic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Figures

Fig. 1.
Fig. 1.
COVID-19 mortality, human development, and BCG vaccination policy by country. (A) Map showing the COVID-19 mortality per million inhabitants in countries worldwide. COVID-19−related deaths per country per million inhabitants denoting countries with low (yellow) to high (red) mortality. (B) COVID-19 mortality per million inhabitants (log) vs. HDI in different countries worldwide. United States data appear by state. (C) Map showing the BCG vaccination policy in countries that currently have universal BCG vaccination program (Current), countries with interrupted BCG vaccination programs (Interrupted), and countries that never implemented a universal vaccination program (Never). Countries without information appear in white.
Fig. 2.
Fig. 2.
Linkage between COVID-19 mortality and BCG vaccination. (A) Coarse analysis of COVID-19 mortality per million inhabitants in countries with current, interrupted, or that never had BCG vaccination programs. United States data appear by state. (B) Filtered analysis of COVID-19 mortality per million inhabitants in countries with current, interrupted, or that never had BCG vaccination programs and similar social, economic, and epidemic stage conditions. (C) Filtered analysis of COVID-19 mortality per million inhabitants in countries with current vs. interrupted or that never had BCG vaccination programs, including only countries with similar social, economic, and epidemic stage conditions. (D) Negative association between percentage of vaccination coverage (mean) between 1980 and 2018, as a proxy of population protection, and maximum COVID-19 deaths per million inhabitants registered by country in a day, as a proxy of COVID-19 severity. Full list of analyses is available in SI Appendix, Tables S2–S4.
Fig. 3.
Fig. 3.
COVID-19 mortality in comparable regions that have had different BCG vaccination policies. (A) COVID-19 mortality by time in populous North and South American States. (Left) COVID-19 mortality per 10 million inhabitants in a 3-d centered average. Time adjusted according to the day with the first death in each region as day 1, up to 25 d of the epidemic. (Right) Table shows population density and COVID-19 mortality by day 25 of the epidemic for each region. Regions that have had BCG vaccination (blue) had lower mortality than regions without BCG vaccination (red; r2 = 0.84, P < 0.001; t [237] = 14.274, P < 0.001). (B) Estimated age range of people that received BCG vaccination in East and West Germany. (C) Map illustrating the regions of East and West Germany included in the analysis. (D) Mean COVID-19 mortality in East Germany was lower than mortality in West Germany (t [11] = −2.592, P = 0.025).
Fig. 4.
Fig. 4.
Variation in COVID-19 mortality and BCG vaccination policy in different European countries. (A) Map illustrating COVID-19 deaths per million inhabitants in European countries. (B) Map illustrating BCG vaccination policy in European countries that currently have universal BCG vaccination program (Current), countries that interrupted in the past a BCG vaccination program (Interrupted), and countries that never implemented a universal vaccination program (Never). (C) BCG index = (age of oldest vaccinated cohort × total number of years of vaccination campaign)/standardization parameter (5,625) × Mean BCG vaccination coverage. (D) Correlation between BCG index and COVID-19 mortality per million inhabitants and in European countries with different BCG vaccination policy. (E) Correlation between BCG index and COVID-19 mortality per million inhabitants during the first month of the pandemic in socially similar European countries with different BCG vaccination policy.
See this image and copyright information in PMC

Update of

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abdallah A. M., Behr M. A., Evolution and strain variation in BCG. Adv. Exp. Med. Biol. 1019, 155–169 (2017). - PubMed
    1. Dye C., Making wider use of the world’s most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered. J. R. Soc. Interface 10, 20130365 (2013). - PMC - PubMed
    1. Colditz G. A. et al. ., The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analyses of the published literature. Pediatrics 96, 29–35 (1995). - PubMed
    1. Luca S., Mihaescu T., History of BCG vaccine. Maedica (Buchar.) 8, 53–58 (2013). - PMC - PubMed
    1. Mangtani P. et al. ., Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials. Clin. Infect. Dis. 58, 470–480 (2014). - PubMed

Publication types

LinkOut - more resources